Yibin Yang
Department of Cancer Research
Fox Chase Cancer Center
United States of America
Biography
Yibin Yang,Educational Background: Postdoctoral Training, National Cancer Institute, National Institutes of Health, Bethesda, MD PhD, Cancer Biology, University of Massachusetts Medical School, Worcester, MA, 2010 BS, Biological Science, Wuhan University, Wuhan, China, 2001 Memberships: American Association for Cancer Research Honors & Awards: NCI K22 Transition Career Development Award, 2016-2019 NIH Fellows Award for Research Excellence, 2015
Research Interest
Immune Signaling and Regulatory Pathways in Hematologic Malignancies Identifying the novel ubiquitin regulator and signaling molecular- “addictions” -of cancer cells that could be exploited therapeutically. Defining the molecular mechanism by which these ubiquitin enzymes and immune pathways contribute to tumor initiation and maintenance. Targeting ubiquitin system and related regulatory pathways to treat human hematologic malignancies.
Publications
-
Yang, Y., Shaffer, A. L., Emre, N. T., Ceribelli, M., Zhang, M., Wright, G., ... & Young, R. M. (2012). Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer cell, 21(6), 723-737.
-
Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.
-
Kelly, P. N., Romero, D. L., Yang, Y., Shaffer, A. L., Chaudhary, D., Robinson, S., ... & Staudt, L. M. (2015). Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. Journal of Experimental Medicine, 212(13), 2189-2201.
-
Yang, Y., & Staudt, L. M. (2015). Protein ubiquitination in lymphoid malignancies. Immunological reviews, 263(1), 240-256.
-
Yang, Y., Kelly, P., Shaffer, A. L., Schmitz, R., Yoo, H. M., Liu, X., ... & Ceribelli, M. (2016). Targeting non-proteolytic protein ubiquitination for the treatment of diffuse large B cell lymphoma. Cancer cell, 29(4), 494-507.
